H ematoma expansion occurs in approximately one third of patients with acute primary intracerebral hemorrhage (ICH) and is independently associated with early neurological deterioration, death, and disability.
prognostication and to assess efficacy of therapies targeted to selected patient cohorts. 3 Intrahematoma contrast extravasation on computerized tomography (CT) angiography (CTA), coined the spot sign, is one of the most promising predictors of hematoma expansion. 4 The spot sign was recently prospectively validated as an independent predictor of hematoma expansion in the Predicting Hematoma Growth and Outcome in Intracerebral Hemorrhage Using Contrast Bolus CT (PREDICT) multicentre cohort study. 5 On the basis of radiological characteristics of the spot sign, a scoring system, the spot sign score (SSS), was devised reporting accurate risk stratification of hematoma expansion based on spot number, maximum spot size, and density. 6 The SSS represents an important development toward an accurate predictive model for hematoma expansion; however, the single-center retrospectively developed scoring system is not externally validated. The purpose of this study was to validate the SSS for prediction of hematoma expansion and to perform an independent evaluation of spot characteristics most predictive of hematoma expansion.
Methods

Patient Cohort and Study Protocol
Patient data were obtained from the PREDICT study, 5 a prospective multicenter cohort study (12 centers in 6 countries) of acute primary or anticoagulant-associated ICH patients presenting within 6 hours of onset. Inclusion criteria included age ≥18 years and ICH volume <100 mL. Exclusion criteria were known renal impairment, premorbid dependence defined as modified Rankin scale score >3, secondary cause of ICH (eg, tumor, arteriovenous malformation), deep coma (Glasgow Coma Scale ≤5), or major comorbid or terminal illness.
Baseline variables recorded included patient demographics, medical history, Glasgow Coma Scale and National Institutes of Health Stroke Scale, coagulation profile, and blood glucose. All data were collected and submitted to the coordinating center at the University of Calgary (Calgary, Canada). Study protocol was approved by the research ethics board at each participating center. Surrogate consent or written informed consent was obtained for each patient according to requirements established by each ethics board site.
Two hundred sixty-eight patients were enrolled in PREDICT from June 24, 2006, to September 6, 2010. Forty patients were excluded from the primary analysis of hematoma expansion (14 treated with recombinant activated factor VII before follow-up CT; 15 treated with surgical evacuation before follow-up CT; 7 died before follow-up CT, and 4 did not have a follow-up CT for unknown reasons). Two hundred twenty-eight (85%) patients had a 24-hour follow-up CT and were included in the study analysis.
Image Acquisition
Imaging performed included baseline noncontrast CT (NCCT), CTA, and 24-hour follow-up NCCT. Time from ictus to NCCT, CTA, and 24-hour follow-up scan was recorded. Delayed angiographic or postcontrast imaging was not included in the study protocol. CT protocols were performed according to standard institutional technique reflecting a pragmatic observational study approach. Site scanners and specific CT protocols are listed in Table I in the online-only Data Supplement.
Image Analysis
CTA source images were independently examined for spot sign presence by 2 experienced neuroradiologists and a radiology resident blinded to 24-hour follow-up CT and hematoma expansion. The spot sign definition is as previously reported. : 1 to 2 spot signs, 1 point; ≥3 spot signs, 2 points; maximum axial dimension ≥5 mm, 1 point; maximum density ≥180 HU, 1 point.
Baseline and 24-hour NCCT hematoma volumes were analyzed with Quantomo, a computerized-planimetry software (Cybertrial Inc, Calgary, Canada), 8, 9 and performed by an neurologist blinded to CTA images. ICH location and presence of intraventricular hemorrhage were recorded from baseline NCCT images by the neuroradiologists.
Statistical Analysis
Primary outcome was clinically significant hematoma expansion defined as ICH volume increase >6 mL or >33%. [4] [5] [6] 10, 11 Secondary outcome measures were hematoma expansion as defined by absolute and relative volume increase expressed in milliliter and percentage, respectively.
Independent association of the SSS with primary outcome was assessed using multivariable logistic regression adjusting for potential confounders of hematoma expansion, including baseline international normalized ratio (INR), mean arterial pressure, time to baseline NCCT, ICH volume, blood glucose, intraventricular hemorrhage presence, and age. 12, 13 Association with secondary continuous outcomes was assessed with log-transformed multivariable linear regression controlling for the same variables. 12 Diagnostic performance for prediction of the primary outcome was assessed for each SSS category, and overall area under the curve (AUC) was assessed using receiver operating characteristic analysis. Exploratory analysis was performed for patients not meeting spot criteria, proposed in the original SSS derivation study, 6 and for nonanticoagulated (INR ≤1.2) patients. Individual spot sign characteristics were examined with receiver operating characteristic analysis to determine optimal AUC for primary outcome prediction. 6 Multivariable logistic regression, using generalized estimating equations to account for potential clustering of spot characteristics by site, was used to determine spot characteristics independently associated with primary outcome.
An exploratory analysis of subthreshold spots was performed to determine whether sensitivity of the spot sign could be improved. McNemar test was used to compare differences in sensitivity and specificity.
To determine whether the SSS improved prediction of primary outcome compared with individual spot characteristics, we performed a parallel analysis between SSS and spot characteristics independently associated with primary outcome. Specifically, we compared receiver operating characteristic curves between SSS and individual significant spot characteristics to determine whether there was an overall difference in primary outcome discrimination. Subsequently, multivariable logistic regression models were created, adjusting for the same potential confounders of hematoma expansion used in the SSS model; however, SSS was replaced with individual significant spot characteristics within the model. Comparison of logistic regression model discrimination was performed using the c-statistic. To further compare SSS and individual significant spot characteristics, tests for trends in proportions and continuous outcomes were assessed using the Cochrane-Armitage test and Cuzick nonparametric test, respectively.
Interobserver agreement for spot sign presence, number, density, and overall SSS was calculated using the multirater κ statistic and intraclass correlation coefficient for categorical and continuous variables, respectively. Values of κ 0.21 to 0.4, 0.41 to 0.6, 0.61 to 0.8, and 0.81 to 1 were considered fair, moderate, substantial, and nearly 
Results
Two hundred twenty-eight patients (mean±SD, 68.7±14.0 years; 57% men) met the study inclusion criteria. Baseline demographic characteristics are described in detail elsewhere. 5 In brief, median (interquartile range, IQR) time from onset to baseline NCCT and CTA was 2.3 (1. 
Spot Sign Score Validation
Multivariable logistic regression for primary outcome prediction, controlling for confounders, demonstrated that SSS was independently associated with hematoma expansion criteria (OR of 1.93 per 1-point increase of SSS, 95% CI, 1.32-2.86; P=0.001). Similarly, multivariable linear regression for secondary outcome also demonstrated independent associations with absolute and relative hematoma expansion (P<0.001 and P=0.009, respectively). Diagnostic performance of the SSS for prediction of hematoma expansion is listed in Table 1 . Risk of significant, absolute, and relative hematoma expansion by SSS is listed in Table 2 . Interobserver agreement for SSS was near perfect (κ=0.82; 95% CI, 0.74-0.89). Exclusion of 3 spots not meeting the 120 HU spot sign cutoff resulted in sensitivity reduction of spot presence to 49% (95% CI, 37%-61%) with increased specificity to 86% (95% CI, 80%-91%). Neither sensitivity nor specificity was significantly changed (McNemar test, P=0.317 and P=0.083, respectively) and no significant difference in overall AUC occurred (0.68 versus 0.68; P=0.978). Exclusion of anticoagulated patients (INR >1.2; n=60) marginally increased the overall AUC for SSS prediction of hematoma expansion to 0.70 (95% CI, 0.62-0.79).
Spot Sign Characteristics
Spot sign characteristics by primary outcome are listed in Table 3 . Interobserver agreement for spot presence and spot number were near perfect (κ=0.90; 95% CI, 0.91-0.99; κ=0.85; 95% CI, 0.77-0.92, respectively). Multirater agreement for spot density and size measurement was excellent (intraclass correlation coefficient, 0.92; 95% CI, 0.81-0.97; intraclass correlation coefficient, 0.83; 95% CI, 0.58-0.92, respectively).
Of all spot characteristics, spot sign number demonstrated the greatest AUC (0.68; 95% CI, 0.62-0.75; P<0.001) and was maximized when patients were categorized according to 0, 1, 2 to 3, and ≥4 spots (AUC, 0.69; 95% CI, 0.62-0.75; P<0.001).
Univariate Tests for trend in primary outcome risk with increasing SSS were not demonstrated among spot-positive patients (P trend=0.720). Similarly, increasing SSS was not associated with absolute and relative hematoma expansion (P trend=0.182 and 0.470, respectively). Exclusion of spots <120 HU and patients with INR >1.2 did not impact tests for trend in primary outcome (P trend=0.172). Spot number category showed significant trends for hematoma expansion risk (P=0.050), and absolute (P<0.001) and relative hematoma expansion (P<0.001).
Discussion
In agreement with the original SSS derivation cohort 6 and a separate prospective single-center study, 14 the present multicenter study confirms that the SSS is an independent predictor of hematoma expansion. Analysis of individual spot characteristics demonstrated that only spot number was associated with hematoma expansion prediction, whereas spot density, size, and relative attenuation were not. A parallel analysis demonstrated that the overall predictive value of spot sign number was similar to the SSS. However, increasing SSS was not associated with increased risk of hematoma expansion among spot-positive patients, whereas increasing spot number alone was.
The inability to observe an association between spot density and size with hematoma expansion despite potential biological plausibility may be multifactorial. Importantly, by design, participating sites in PREDICT used local CTA protocols reflecting the current state of CTA-use worldwide. CT attenuation measurements without contrast medium alone have demonstrated large variations in absolute HU measurements in phantoms between CT vendors and acquisition parameters. 15 Additional differences relating to varying contrast medium concentrations, volume, injection speed, acquisition triggering, and timing between sites potentially further contribute to variations in spot density and size. Accounting for potential clustering of spot characteristics among sites and examining relative attenuation measurements, we were unable to observe an association between spot density and size with increasing risk of expansion. Therefore, the use of spot density and size to risk stratify hematoma expansion in a multicenter setting may be impractical in the absence of protocol harmonization. Further, precise measurement of density and size may be practically challenging in the acute setting. Despite protocol heterogeneity, we were able to demonstrate a significant association between spot number and increasing hematoma expansion risk, suggesting that spot number alone provides sufficient risk stratification for expansion risk as applied to current real-world clinical practice. An advantage of spot number compared with SSS is that number should be easily assessable by clinicians in the emergency department without the need to calculate a score.
Exploratory analysis of subthreshold intrahematoma contrast densities (without density twice that of background hematoma) demonstrated significant improvement in sensitivity for hematoma expansion prediction when included within the 
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April 2013 spot definition. Prior definitions used arbitrary absolute and relative density cutoff thresholds, yet the optimal threshold remains unknown. 6, 7 Inclusion of any contrast density seems more intuitive because faintly appearing densities may represent early imaging of a spot before maximal opacification. 4, 16 Prior studies have demonstrated varying rates of spot appearance indicating variable rates of contrast leak. 6, 17, 18 Addition of delayed imaging to routine CTA demonstrates ≈8% more ICH patients with extravasation and increases sensitivity for prediction of hematoma expansion and poor clinical outcome. 6, 17, 19 Recently, dynamic spot imaging using CT perfusion demonstrated 21% improved spot number detection. The peak time to maximal contrast density was 50 seconds after contrast bolus injection. 20 Inclusion of dynamic or delayed imaging will yield the greatest number of spots detected and improve diagnostic performance for hematoma expansion prediction. Prognostic characteristics of dynamic and delayed spots will require further characterization; however, the number of spots detected will likely remain a critical determinant for risk stratification.
Potential study limitations include different inclusion/ exclusion criteria from the original SSS studies, specifically inclusion of anticoagulated patients and slight variation in spot definition compared with the original SSS derivation study. Analysis of nonanticoagulated patients and exclusion of spots not meeting the original SSS derivation definition, however, did not significantly alter results. Also, specific contrast bolus concentration and CTA timing were not mandated in the PREDICT protocol precluding a detailed analysis of potential confounders and their effect on spot characteristics. Each center was, however, experienced in the use of CTA and used protocols represented the best clinical techniques.
Conclusions
Multicenter external validation of the SSS demonstrates that spot number alone provides similar hematoma expansion prediction and improved hematoma expansion risk stratification compared with the SSS using first-pass CTA. Spot number should aid ICH prognostication and may be useful in patient selection for future ICH therapeutic studies. 
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